<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997460</url>
  </required_header>
  <id_info>
    <org_study_id>8.1-21/4-2, 02/21 AG</org_study_id>
    <nct_id>NCT04997460</nct_id>
  </id_info>
  <brief_title>Diabetes Type One in Pregnancy and Continuos Glucose Monitoring</brief_title>
  <acronym>DIP1/CRO</acronym>
  <official_title>Diabetes Type One in Pregnancy and Continuous Glucose Monitoring - Observational Prospective Study in Croatia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Hospital Centre Zagreb</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Hospital Centre Zagreb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type I diabetes mellitus (T1DM) affects about 0.1-0.2% of all pregnancies. T1DM in pregnancy&#xD;
      increases the risk of maternal and neonatal complications.&#xD;
&#xD;
      Continuous glucose monitoring systems (CGM) provide a continuous display of measured glucose.&#xD;
      Studies have shown improved pregnancy outcomes for patients with T1DM using CGM when compared&#xD;
      to capillary blood glucose measurements.&#xD;
&#xD;
      This prospective observational study analyses impact of glycemic variability on development&#xD;
      of large-for-gestational-age neonates and effects of hypoglycemia during pregnancy on&#xD;
      pregnancy outcomes.&#xD;
&#xD;
      Furthermore, overall glycemic regulation, different insulin metrics and C-peptide&#xD;
      concentration during pregnancy will also be assesed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 200 patients with type one diabetes will be enrolled in the study during first&#xD;
      trimester of pregnancy. Medical history, clinical examination, anthropometric measurements&#xD;
      and laboratory work-up will be obtained at first visit. Glucose metrics are provided from&#xD;
      continuous glucose monitoring systems and blood glucose measurements .&#xD;
&#xD;
      Following the initial evaluation, patients will be regularly examined in the hospital setting&#xD;
      once a month during pregnancy. Following evaluations will include the same procedures as the&#xD;
      first one.&#xD;
&#xD;
      Pregnancy outcomes that will be analysed: spontaneous abortion, preterm birth,&#xD;
      large-for-gestational-age neonates, macrosomia, small-for-gestational-age neonates, birth&#xD;
      weight, congenital anomalies, APGAR score, neonatal hypoglycemia, intensive care unit&#xD;
      admission for mother and/or infant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">January 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of large-for-gestational-age neonates</measure>
    <time_frame>9 months</time_frame>
    <description>Incidence of large-for-gestational-age neonates will be determined in group of patients with increased glycemic variability (%CV&gt; 36%) and in the group of patients with normal glycemic variability (%CV &lt; 36%) during different pregnancy trimesters.&#xD;
Glycemic variability parameters are available from continuous glucose monitoring system:percent coefficient of variation (%CV), interquartile range (IQR), standard deviation (SD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of glycated hemoglobin and glycemic variability</measure>
    <time_frame>9 months</time_frame>
    <description>Correlation of glycemic variability parameters (%CV, IQR, SD) and glycated hemoglobin in different pregnancy trimesters will be performed.Both parameters are available from continuos glucose monitoring systems.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcomes - maternal and fetal</measure>
    <time_frame>9 months</time_frame>
    <description>Effects of hypoglycemia on pregnancy outcomes will be analysed. Pregnancy outcomes included in the analysis: spontaneous abortion, preterm birth, large-for-gestational-age neonates, macrosomia, small-for-gestational-age neonates, birth weight, congenital anomalies, APGAR score, neonatal hypoglycemia, intensive care unit admission for mother and/or infant.&#xD;
Hypoglycemia will be assesed through parameters available from continuos glucose monitoring systems (low glucose events, time spent below target).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of hypoglycemia and glycemic variability</measure>
    <time_frame>9 months</time_frame>
    <description>Correlation between hypoglycemia parameters (time below target, low glucose events) and glycemic variability parameters (%CV, SD, IQR) will be performed. Both parameters are available from continuous glucose monitoring systems.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>C-peptide concentration in different pregnancy trimesters</measure>
    <time_frame>9 months</time_frame>
    <description>C-peptide concentration will be determined from venous blood sample in every pregnancy trimester.</description>
  </other_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Large-for-gestational-age Neonates</condition>
  <condition>Glycemic Variability</condition>
  <condition>Hypoglycemia</condition>
  <condition>Pregnancy Outcomes</condition>
  <condition>C-peptide</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients enrolled in the study are women who are patients of the Clinic for gynecology and&#xD;
        obstetrics and who match the inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed diagnosis of type one diabetes&#xD;
&#xD;
          -  duration of the disease for minimum of one year before inclusion in the study&#xD;
&#xD;
          -  multiple daily insulin injection therapy or insulin pump&#xD;
&#xD;
          -  glycemia monitoring with continuous glucose monitoring systems (FreeStyle Libre Flash&#xD;
             Glucose Monitoring System, Abott) for a minimum of 3 months before inclusion in the&#xD;
             study&#xD;
&#xD;
          -  glucose data availability from the sensor &gt; 80% for a determined period of monitoring&#xD;
&#xD;
          -  patient age &gt; 18 years and &lt; 40 years&#xD;
&#xD;
          -  available medical records from the preconception period (3 months before conception)&#xD;
&#xD;
          -  first trimester of pregnancy&#xD;
&#xD;
          -  body mass index &lt; 25kg/m2&#xD;
&#xD;
          -  glycated haemoglobin &lt; 7.0%&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other types of diabetes except type one: type 2 diabetes, diabetes developed during&#xD;
             pregnancy, diabetes as a result of genetic defect of beta-cells of the pancreas&#xD;
&#xD;
          -  using other therapy besides insulin in treating diabetes&#xD;
&#xD;
          -  changes to the specific insulin therapy in preconception period or during pregnancy;&#xD;
             defined as switching from multiple daily insulin injection therapy to insulin pumps&#xD;
             and vice versa&#xD;
&#xD;
          -  patient's inability for regular hospital visits (defined as once monthly during&#xD;
             pregnancy)&#xD;
&#xD;
          -  patients unable to understand the protocol and the goal of the study&#xD;
&#xD;
          -  patients unable to read and write&#xD;
&#xD;
          -  multiple pregnancy&#xD;
&#xD;
          -  glycated haemoglobin &gt; 7.0% in all pregnancy trimesters&#xD;
&#xD;
          -  significant weight gain during pregnancy (&gt;20 kilograms)&#xD;
&#xD;
          -  glucose data availability from the sensor &lt; 80%&#xD;
&#xD;
          -  unavailability of preconception medical records&#xD;
&#xD;
          -  unavailability of medical records from pregnancy and pregnancy outcomes&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maja Baretic</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Hospital Centre Zagreb</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Ivanisevic</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Hospital Centre Zagreb</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gloria Leksic</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Hospital Centre Zagreb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloria Leksic</last_name>
    <phone>00385977818746</phone>
    <email>gleksic@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maja Baretic</last_name>
    <email>mbaretic@kbc-zagreb.hr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Leksic</last_name>
      <email>gleksic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marija Radic</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lara Gudelj</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Hospital Centre Zagreb</investigator_affiliation>
    <investigator_full_name>Gloria Leksic</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Macrosomia</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

